Printer Friendly

ACETO Subsidiary to unveil lithium carbonate extended-release tablets and metronidazole tablets in the US market.

M2 EQUITYBITES-March 24, 2016-ACETO Subsidiary to unveil lithium carbonate extended-release tablets and metronidazole tablets in the US market

(C)2016 M2 COMMUNICATIONS http://www.m2.com

Human Health products company ACETO Corporation (NasdaqGS:ACET) stated on Wednesday that it plans to introduce Lithium Carbonate Extended-release Tablets, 300mg and Metronidazole Tablets, 250mg and 500mg in the US market.

This launch is being initiated by the company's finished dosage form generics subsidiary, Rising Pharmaceuticals Inc.

The company added that Lithium Carbonate Extended-release Tablets, 300mg is an US FDA approved generic version of ANI Pharmaceutical's Lithobid and Metronidazole Tablets, 250mg and 500mg is an US FDA approved generic version of GD Searle, LLC's Flagyl.

For the 12 months ended 31 January 2016, theUS market sales for Lithium Carbonate Extended-release Tablets, which is used in the treatment of manic-depressive illness, were approximately USD21m, according to IMS Health data.

In addition, the US market sales for Metronidazole Tablets, which is used in the treatment of trichomoniasis, asymptomatic consorts, amebiasis and a variety of anaerobic bacterial infections, were about USD51m for the 12 months ended 31 January 2016.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Mar 24, 2016
Words:193
Previous Article:Vetter plans to build new building in Q1 of 2018.
Next Article:Minerals Technologies to supply metallurgical wire to Big River Steel LLC.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters